
Bioequivalence affects not only treatment quality, but also everyday clinical decisions. With the help of an expert, we explore the scope of the terms and regulations involved.
Article originally published in Intramed, with the participation of our team as a specialized source on the subject.
View full article on IntramedOn 01/20/2026, ANMAT Salud published Disposition 47/2026 in the Official Gazette, updating the list of APIs that must undergo bioequivalence/bioavailability studies.
Read moreDr. Ethel Feleder, our Director, was selected by ANMAT to join the Network of Experts in Pharmacological Clinical Research.
Read more